The Global Fanconi Anemia Drug Market Growth Accelerated By Rising Disease Prevalence
Fanconi Anemia Drug Market |
Fanconi
anemia is a rare genetic blood disorder that causes bone marrow failure and
increased risk of developing certain types of cancers such as acute myeloid
leukemia. Fanconi anemia drugs are typically used for managing symptoms,
treating complications, and improving quality of life. Drugs such as
L-carnitine, androgen therapy, antibiotics, antifungals, hematopoietic stem
cell transplantation are prescribed based on individual needs and disease
severity.
The
global Fanconi Anemia Drug Market is estimated to be valued at US$ 574.4 Mn in 2023 and is expected to
exhibit a CAGR of 9.7% over the
forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of Fanconi anemia globally is the primary driver
propelling the growth of this market. According to the National Organization
for Rare Disorders, the estimated birth incidence of Fanconi anemia ranges from
1 in 100,000 to 1 in 300,000 live births globally. Advances in screening and
diagnostic techniques have aided early detection rates. Furthermore, increasing
research activities focused on developing novel therapeutics are encouraging
pharmaceutical manufacturers to invest in drug development programs. Several
drugs are progressing through preclinical and clinical trial phases which is
expected to boost the market during the forecast period.
Segment Analysis
The global Fanconi Anemia Drug market is segmented by drug type, distribution
channel, and geography. By drug type, the market is divided into Afatinib
Dimaleate, Dezaguanine Mesylate, and Others. Among these, Afatinib Dimaleate
segment holds the largest market share as it is the only FDA approved drug for
Fanconi anemia treatment. It is highly effective in managing bone marrow
failure and rare types of anemia associated with Fanconi anemia.
By distribution channel, hospitals & retail pharmacies segment dominates
the market due to strong existing distribution network of generic drugs.
However, online pharmacies segment is expected to witness highest growth during
the forecast period due to growing e-commerce platforms and increasing
preference for online shopping.
Key Takeaways
The Global
Fanconi Anemia Drug Market Demand is
expected to witness high growth. The global Fanconi Anemia Drug Market is
estimated to be valued at US$ 574.4 Mn in 2023 and is expected to exhibit a
CAGR of 9.7% over the forecast period 2023 to 2030.
North America leads the global market and is expected to maintain its dominance
during the forecast period. High prevalence of Fanconi anemia and presence of
key market players in the US drives market growth. According to the National
Institutes of Health report, prevalence of Fanconi anemia in the US is 1 in
every 130,000 newborns. Europe is the second largest market for Fanconi anemia
drugs. Rising R&D investments by governments and pharma companies in Europe
contributes to regional market growth.
Key players related content comprises:
Key players operating in the Fanconi Anemia Drug market are Aetna Inc., AIA
Group Limited, Allianz, Assicurazioni Generali S.P.A., AVIVA, AXA, CIGNA, and
UnitedHealth Group Inc.
Get
more insights on this topic:
https://www.marketwebjournal.com/fanconi-anemia-drug-market-market-size-and-share-analysis/
Comments
Post a Comment